December 3, 2014
San Diego, Calif., Dec 3, 2014 – Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced its participation on two panel discussions at the Genetic Rx Conference taking place at Harvard Medical School on December 3, 2014.
Dr. Pad Chivukula, COO and CSO, and Joseph E. Payne, President & CEO of Arcturus Therapeutics, will present on “The Importance Of Collaboration” and “RNAi, Antisense and RNA Activation Approaches: The Promise and The Challenge” at 1:00-1:30 pm EST and 4:00-4:30 PM EST, respectively.
“Our collaborative efforts have played an integral role in successfully advancing our pipeline of RNA medicines,” said Dr. Pad Chivukula, COO and CSO of Arcturus Therapeutics, Inc.
“Arcturus technologies and medicines have the unique ability to control gene expression in both directions, said Joseph E. Payne, President & CEO of Arcturus Therapeutics. “UNA Oligomer™ chemistry and LUNAR™ delivery can enable small interfering RNA to knockdown gene expression – and also empower messenger RNA to up-regulate gene expression. We are honored to participate in two panels at this great conference.”
About the Boston Biotech Conferences (BBC)
The Boston Biotech Conferences (BBC) mission is to build a vibrant community of bio-Pharma leaders, which will help to drive innovation in biotech, and bring important drugs to patients more quickly. The conferences are exclusive, thought-leader forums for senior bio-Pharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking and corporate development within the bio-Pharma community. The meetings are invitation-only, off-the-record forums that bring together the past, present and future leaders in the healthcare community to network, exchange ideas and share insights into the industry’s challenges and opportunities. For more information, visit http://www.bbbiotechconference.com.
About Transthyretin (TTR)-Mediated Amyloidosis
Transthyretin (TTR)-mediated amyloidosis is a genetically mediated fatal disease caused by mutations in the TTR gene. Mutated TTR, which is mainly synthesized in the liver, causes errant amyloid proteins to aggregate and deposit, destroying body organs and tissue, such as the peripheral nerves and heart. TTR-mediated cardiomyopathy (FAC) affects approximately 40,000 people with the mean survival of ~2.5 years. TTR-mediated polyneuropathy (FAP) affects at least 10,000 people. There is a substantial unmet need for effective medicines for patients suffering from TTR-mediated diseases.
About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. Arcturus has developed a novel, potent and safe RNA Therapeutics platform called LUNAR™, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, antisense RNA, and microRNA oligotherapeutics. The company’s UNA Oligomer™ chemistry technology and patent portfolio (34 patents, USPTO granted) enables the targeting of any gene in the human genome. For more information, visit www.ArcturusRx.com.
# # #